From lead to preclinical candidate: Optimization of β-homophenylalanine based inhibitors of dipeptidyl peptidase IV

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 16, 2009, Pages 4818-4823

  Nordhoff, Sonja ^a   López Canet, Meritxell ^a   Hoffmann Enger, Barbara ^a   Bulat, Stephan ^a   Cerezo Gálvez, Silvia ^a   Hill, Oliver ^a   Rosenbaum, Claudia ^a   Rummey, Christian ^a   Thiemann, Meinolf ^a   Matassa, Victor G ^a   Edwards, Paul J ^a   Feurer, Achim ^a  

^a Santhera Pharmaceuticals   (Switzerland)

Author keywords

Dipeptidyl peptidase IV; DPP 4; DPP IV; GLP 1; Glucagon like peptide 1; Type 2 diabetes

Indexed keywords

BETA HOMOPHENYLALANINE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; RAT; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; AMINOBUTYRIC ACIDS; ANIMALS; CACO-2 CELLS; CELL LINE, TUMOR; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOGS; HUMANS; HYDROCARBONS, FLUORINATED; HYPOGLYCEMIC AGENTS; PROTEASE INHIBITORS; PYRROLIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67651087356     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.06.036     Document Type: Article

References (25)

1. For selected recent reviews, see:. von Geldern T.W., and Trevillyan J.M. Drug Dev. Res. 67 (2006) 627
2. Augustyns K., Van der Veken P., and Haemers A. Exp. Opin. Ther. Pat. 15 (2005) 1387
3. Weber A.E. J. Med. Chem. 47 (2004) 4135
4. For authoritative reviews, see:. Mentlein R. Regul. Peptides 85 (1999) 9
5. Rosenblum J.S., and Kozarich J.W. Curr. Opin. Chem. Biol. 7 (2003) 496
6. Mentlein R., Gallwitz B., and Schmidt W.E. Eur. J. Biochem. 214 (1993) 829
7. Kieffer T.J., McIntosh C.H.S., and Pederson R.A. Endocrinology 136 (1995) 3585
8. Lene H., Deacon C.F., Orskov C., and Holst J.J. Endocrinology 140 (1999) 5356
9. For selected references, see:. Holst J.J., and Deacon C.F. Diabetes 47 (1998) 1663
10. Knudsen L.B. J. Med. Chem. 47 (2004) 4128
11. Deacon C.F., Ahrén B., and Holst J.J. Exp. Opin. Invest. Drugs 13 (2004) 1091
12. Drucker D.J., and Nauck M.A. Lancet 368 (2006) 1696
13. Kim D., Wang L., Beconi M., Eiermann G.J., Fischer M.H., Huaibing H., Hickey G.J., Kowalchick J.E., Leiting B., Lyons K., Marsilio F., McCann M.E., Patel R.A., Petrov A., Scapin G., Patel S.B., Sinha Roy R., Wu J.K., Wyvratt M.J., Zhang B.B., Zhu L., Thornberry N.A., and Weber A.E. J. Med. Chem. 48 (2005) 141
14. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., Mangold B.L., Russell M.E., and Hughes T.E. J. Med. Chem. 46 (2003) 2774
15. Augeri D.J., Robl J.A., Betebenner D.A., Magnin D.R., Khanna A., Robertson J.G., Wang A., Simpkins L.M., Taunk P., Huang Q., Han S.-P., Abboa-Offei B., Cap M., Xin L., Tao L., Tozzo E., Welzel G.E., Egan D.M., Marcinkeviciene J., Chang S.Y., Biller S.A., Kirby M.S., Parker R.A., and Hamann L.G. J. Med. Chem. 48 (2005) 5025
16. Feng J., Zhang Z., Wallace M.B., Stafford J.A., Kaldor S.W., Kassel D.B., Navre M., Shi L., Skene R.J., Asakawa T., Takeuchi K., Xu R., Webb D.R., and Gwaltney S.L. J. Med. Chem. 50 (2007) 2297
17. Nordhoff S., Cerezo-Gálvez S., Deppe H., Hill O., López-Canet M., Rummey C., Thiemann M., Matassa V.G., Edwards P.J., and Feurer A. Bioorg. Med. Chem. Lett. 19 (2009) 4201
18. 50 value.
19. Edmondson S.D., Mastracchio A., Beconi M., Colwell L.F., Habulihaz B., He H., Kumar S., Leiting B., Lyons K.A., Mao A., Marsilio F., Patel R.A., Wu J.K., Zhu L., Thornberry N.A., Weber A.E., and Parmee E.R. Bioorg. Med. Chem. Lett. 14 (2004) 5151
20. Experimental details can be found in: WO2005/056003.
21. The assay was performed as described in:. Nordhoff S., Cerezo-Gálvez S., Feurer A., Hill O., Matassa V.G., Metz G., Rummey C., Thiemann M., and Edwards P.J. Bioorg. Med. Chem. Lett. 16 (2006) 1744
22. For a detailed discussion on DPP-8 and DPP-9 inhibition with respect to toxicity, please see:. Lankas G.R., Leiting B., Roy R.S., Eiermann G.J., Beconi M.G., Biftu T., Chan C.-C., Edmondson S., Feeney W.P., He H., Ippolito D.E., Kim D., Lyons K.A., Ok H.O., Patel R.A., Petrov A.N., Pryor K.A., Qian X., Reigle L., Woods A., Wu J.K., Zaller D., Zhang X., Zhu L., Weber A.E., and Thornberry N.A. Diabetes 54 (2005) 2988
23. Burkey B.F., Hoffmann P.K., Hassiepen U., Trappe J., Juedes M., and Foley J.E. Diabetes, Obes. Metab. 10 (2008) 1057
24. Connolly B.A., Sanford D.G., Chiluwal A.K., Healey S.E., Peters D.E., Dimare M.T., Wu W., Liu Y., Maw H., Zhou Y., Li Y., Jin Z., Sudmeier J.L., Lai J.H., and Bachovchin W.W. J. Med. Chem. 51 (2008) 6005
25. Compound (3 mg/kg) or vehicle were administered po to ob/ob mice 30 min prior to an oral glucose challenge of 1 g/kg. Time points for blood glucose measurement were -30 (shortly prior to the administration of test item); 0, 15, 30, 60, 90 and 180 min after glucose application. Data are expressed as mean ± SEM (n = 12/group).